Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Zdravljenje metastatskega malignega melanoma z vemurafenibom : klinični primer
Authors:ID Boc, Marko (Author)
ID Boc, Nina (Author)
ID Mesti, Tanja (Author)
ID Reberšek, Martina (Author)
Files:.pdf PDF - Presentation file, download (382,04 KB)
MD5: 135BAF562B0D46B26D29F08EBD0E4EEF
Typology:1.04 - Professional Article
Organization:Logo OI - Institute of Oncology
Keywords:maligni melanom, metastaze, zdravljenje, vemurafenib, tarčna zdravila
Year of publishing:2013
Publication status in journal:Published
Article version:Publisher's version of article
Number of pages:str. 143-146, 157
Numbering:Letn. 17, št. 2
ISSN on article:1408-1741
COBISS.SI-ID:1682299 New window
Copyright:by Authors
Publication date in DiRROS:31.08.2018
AddThis uses cookies that require your consent. Edit consent...

Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija : strokovni časopis za zdravnike
Shortened title:Onkologija
Publisher:Onkološki inštitut
COBISS.SI-ID:65324032 New window


License:CC BY 4.0, Creative Commons Attribution 4.0 International
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Title:Treatment of metastatic malignant melanoma with vemurafenib - case report
Abstract:In Slovenia, just like everywhere else in the world, we are witnessing an upward trend in the incidence of malignant melanoma of the skin. According to the data from the 2009 Cancer Registry of Slovenia, Slovenia recorded 298 and 415 new cases of malignant melanoma in the years 2000-2004 and 2005-2009, respectively. It is estimated that in 2012, there were 555 new cases of malignant melanoma. This melanoma is more common in women than in men, and it represents the sixth most common malignancy in women and the eight most common malignancy in men (1). A multidisciplinary approach in the treatment of malignant melanoma is necessary to ensure the best possible outcome for the patient. Collaboration between the dermatologist, surgeon, pathologist, medical oncologist and radiotherapy specialist is important and necessary. The most important are prevention and early detection, because it is crucial to detect the disease soon early, when it is still curable. The higher the stage of the disease at detection, the greater the likelihood of distant metastases when the disease becomes incurable. This happens in more than 50% of patients with stage 3 malignant melanoma. Median survival for metastatic disease is short (6-9 months), and until the use of newer medicines, it rarely exceeded 12 months (2). However, new hope for patients comes with new targeted therapies, such as vemurafenib and ipilimumab, which, according to the currently available data, provide better response rates and prolong the survival of patients with metastatic malignant melanoma as opposed to cytostatic drugs (3, 4). In our clinical case, we present a patient with metastatic malignant melanoma who has been treated with a number of lines and types of systemic therapy, including vemurafenib, a selective inhibitor of the oncogenic BRAFV600E mutant kinase.